Vinorelbine
|
|
|
- CAS-Nr.
- 71486-22-1
- Englisch Name:
- Vinorelbine
- Synonyma:
- CL069;CS-404;F 80520;NSC32797;NSC 32797;NSC-32797;NVBKW-2307;VINORELBINE;Navelbine(R);KW 2307 base
- CBNumber:
- CB3469220
- Summenformel:
- C45H54N4O8
- Molgewicht:
- 778.93
- MOL-Datei:
- 71486-22-1.mol
|
Vinorelbine Eigenschaften
- alpha
- D20 +52.4° (c = 0.3 in CHCl3)
- Dichte
- 1.36±0.1 g/cm3(Predicted)
- storage temp.
- Store at 4°C, protect from light
- Löslichkeit
- >25.9mg/mL in DMSO
- Aggregatzustand
- Powder
- pka
- 11.36±0.60(Predicted)
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
 
|
| Alarmwort |
Achtung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H301 |
Giftig bei Verschlucken. |
Akute Toxizität oral |
Kategorie 3 |
Achtung |
![GHS hazard pictograms]() src="/GHS06.jpg" width="20" height="20" /> |
P264, P270, P301+P310, P321, P330,P405, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
| H341 |
Kann vermutlich genetische Defekte verursachen. |
Keimzellmutagenität |
Kategorie 2 |
Warnung |
|
P201,P202, P281, P308+P313, P405,P501 |
|
| Sicherheit |
| P260 |
Dampf/Aerosol/Nebel nicht einatmen. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
|
Vinorelbine Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Vinorelbine is a semisynthetic vinca alkaloid differing from vinblastine in the catharantine
moiety of the molecule. It is claimed to have a broad spectrum of action both in vifro and
in vivo; clinically it has been found effective in the treatment of non-small cell lung
cancer, advanced breast cancer, ovarian cancer and Hodgkins disease.
Verwenden
Vinorelbine base is an antineoplastic agent with anti-mitotic properties.
Definition
ChEBI: A vinca alkaloid with a norvinblastine skeleton.
Pharmakokinetik
This semisynthetic alkaloid is unique in having oral bioavailability, but it currently is available only for IV injection. The initial phase elimination half-life is on par with that observed for vincristine and vinblastine, and the terminal phase half-life is between 28 and 44 hours.
Clinical Use
Vinorelbine is particularly useful in the treatment of
advanced non–small cell lung cancer and can be administered
alone or in combination with cisplatin. It is
thought to interfere with mitosis in dividing cells through
a relatively specific action on mitotic microtubules.
Nebenwirkungen
Although dose-limiting granulocytopenia is the major adverse effect, potentially fatal interstitial pulmonary changes have been noted, and patients with symptoms of respiratory distress should be promptly evaluated. As with all vinca alkaloids, elimination is primarily hepatobiliary, and dosage reduction should be considered in patients with liver dysfunction.
Vinorelbine Upstream-Materialien And Downstream Produkte
Upstream-Materialien
3',4'-Anhydrovinblastine
Vinorelbine tartrate
Butyllithium
Magnesium
Aspidospermidin-3-carbonsure, 4-(Acetyloxy)-6,7-didehydro-3-hydroxy-16-methoxy-1-methyl-, Methylester, (2β,3β,4β,5α,12β,19α)-
Essigsure
Allylbromid
Lithium Aluminum Hydride
1,2-Dibromethan
N,N-Diethylethanamin
1-Chlorethylchlorformiat
Trifluoressigsäure
Formaldehyd
Natriumnaphthalid
1-(PHENYLSULFONYL)INDOLE
Downstream Produkte
Vinorelbine Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 211)Lieferanten
71486-22-1()Verwandte Suche:
Silibinin
Vinblastinsulfat
6-Amino-8-(((aminocarbonyl)oxy)-methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino-(2',3': 3,4)pyrrolo(1,2-a)indol-4,7-dion,(1aS-(1a alpha, 8 beta, 8a alpha,8b alpha))-
Methotrexate
Etoposid
Vincristinsulfat
- ANX-530, KW-2307, 5'-Noranhydrovinblastine
- nor-5’-anhydrovinblastine
- VINORELBINE
- (2β,3β,4β,5α,12R,19α)-4-(Acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(Methoxycarbonyl)-2,6-Methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-Methoxy-1-Methyl-aspidosperMidine-3-ca
- 5-Noranhydrovinblastine
- 3’，4'-Didehydro-4ideoxy-C’-norvincaleukoblastine
- NVBKW-2307
- 3',4'-Didehydro-4'-deoxy-C'-norvincaleukoblastine
- Vinorelbine(Navelbine)
- Navelbine(R)
- Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-
, methyl ester, (2b,3b,4b,5a,12R,19a)-
- Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2b,3b,4b,5a,12b,19a)-
- Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2b,3b,4b,5a,12R,19a)- (9CI)
- C'-Norvincaleukoblastine, 3',4'-didehydro-4'-deoxy-
- F 80520
- KW 2307 base
- Navelbine base
- 3’,4’-didehydro-4’-deoxy-c’-norvincaleukoblastin
- vinorelbine D-tartrate
- AspidosperMidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8
- CS-404
- Vinblastine Impurity K
- Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2β,3β,4β,5α,12R,19α)-
- Vinorelbine USP/EP/BP
- Vinorelbine (KW-2307)
- NSC 32797
- NSC32797
- NSC-32797
- CL069
- Vinorelbine, 98%, from Catharanthus roseus (L.) G. Don
- vinorelbine ditartrate ,navelbine,nvb
- Vinorelbine EP Impurity C (2R,8S-Isomer)
- Methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-3a-ethyl-9-((2R,6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl)-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate
- 71486-22-1
- C45H54N4O8
- ZOMIG
- reference standards from Chinese medicinal herbs (TCM).
- standardized herbal extract
- chemical reagent
- pharmaceutical intermediate
- phytochemical
- Active Pharmaceutical Ingredients
- Antineoplastic
